Pristimerin has anticancer activity, treatment with Pristimerin may be a potential strategy for the suppression of hypoxia-induced metastasis through the reversal of hypoxia-induced stem cell characteristics and EMT in cancer cells.

ADTL-SA1215 is a selective SIRT3 activator with SIRT3 deacetylase activity that inhibits the proliferation and migration of human breast cancer MDA-MB-231 cells through the SIRT3-driven autophagy/mitochondrial autophagy signaling pathway, and can be used in the study of triple negative breast cancer.

N-Caffeoyltryptophan, a potential Sirt inhibitor, is screened using coffee extract. N-Caffeoyltryptophan inhibited Sirt2 (IC50; 8.7 μM) better than Sirt1(IC50; 34μM).